Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
NCT ID: NCT00073749
Last Updated: 2018-12-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
79 participants
INTERVENTIONAL
2003-08-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inotuzumab ozogamicin
Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2
Inotuzumab ozogamicin [CMC-544]
CMC-544, IV, dose escalation trial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inotuzumab ozogamicin [CMC-544]
CMC-544, IV, dose escalation trial
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At the expanded cohort, part 2 of the study, subjects must have one of the following:
* Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy
* Diffuse large B-cell lymphoma
* Age 18 years or older
Exclusion Criteria
* Chronic lymphocytic leukemia
* Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB CCC Clinical Studies Unit
Birmingham, Alabama, United States
University of Alabama at Birmingham Kirklin Clinic
Birmingham, Alabama, United States
UAB Russell Ambulatory Pharmacy
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Northwestern Medical Faculty Foundation
Chicago, Illinois, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
M.D. Anderson Cancer Center
Houston, Texas, United States
Universitair Ziekenhuis Gasthuisberg
Leuven, , Belgium
Hopital Saint Louis
Paris, , France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, , France
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet
Mainz, , Germany
Medizinische Klinik und Poliklinik III, Klinikum der Universitat Muenchen-Grosshadern
München, , Germany
Universitaet Muenchen Klinikum Grosshadern
München, , Germany
Hospital de la Santa Creu I Sant Pau
Barcelona, , Spain
Hospital Clinic I Provincial
Barcelona, , Spain
Centre Hospitalier Universitaire Vaudois
Lausanne, , Switzerland
St Bartholomew's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1931002
Identifier Type: OTHER
Identifier Source: secondary_id
3129K1-100
Identifier Type: -
Identifier Source: org_study_id